A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North central cancer treatment group study N0528

Journal of Thoracic Oncology

Volumn 8, Issue 1, 2013, Pages 79-88

  Adjei, Alex A ^a   Dy, Grace K ^a   Mandrekar, Sumithra J ^b   Nelson, Garth D ^b   Meyers, Jeffrey P ^b   Adjei, Araba A ^a   Ross, Helen J ^c   Ansari, Rafat H ^d   Lyss, Alan P ^e   Stella, Philip J ^f   Schild, Steven E ^c   Molina, Julian R ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

^c MAYO CLINIC   (United States)

^d Missouri Baptist Cancer Center ^*  (United States)

^e MISSOURI BAPTIST MEDICAL CENTER   (United States)

^f ST JOSEPH MERCY HOSPITAL   (United States)

Author keywords

Carboplatin; Cediranib; Gemcitabine

Indexed keywords

ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; CARBOPLATIN; CEDIRANIB; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GEMCITABINE; VASCULOTROPIN RECEPTOR 3;

ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ASSESSMENT; CLINICAL PROTOCOL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE EXPRESSION; HAZARD RATIO; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84871977845     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318274a85d     Document Type: Article

References (51)

1. Pfster DG, Johnson DH, Azzoli CG, et al.; American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresect-able non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-353.
2. Azzoli CG, Baker S Jr, Temin S, et al.; American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-6266.
3. Schiller JH, Harrington D, Belani C P, et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
4. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550.
5. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-1186.
6. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22:2184-2191.
7. Ramalingam SS, Dahlberg SE, Langer CJ, et al.; Eastern Cooperative Oncology Group. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with car-boplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008;26:60-65.
8. Laurie SA, Arnold A, Gauthier I, et al: Final results of a phase I study of daily oral azd2171, an inhibitor of vascular endothelial growth factor receptors (vegfr), in combination with carboplatin I + paclitaxel (t) in patients with advanced non-small cell lung cancer (nsclc): a study of the national cancer institute of Canada clinical trials group (ncic ctg). J Clin Oncol 2006;24:18s (abstr 3054).
9. Laurie SA, Gauthier I, Arnold A, et al. Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institute of Canada clinical trials group. J Clin Oncol 2008;26:1871-1878.
10. Goss GD, Laurie S, Shepherd F, et al: Phase I study of daily oral azd2171, a vascular endothelial growth factor receptor inhibitor (VEGRFI), in combination with gemcitabine and cisplatin (g/c) in patients with advanced non-small cell lung cancer (ANSCLC): a study of the NCIC clinical trials group. J Clin Oncol 2007;25:18s (abstr 7649).
11. Goss G, Shepherd FA, Laurie S, et al. A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: a study of the National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 2009;45:782-788.
12. Tian C, Ambrosone CB, Darcy KM, et al. Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 2012;124:575-581.
13. Wedge SR, Kendrew J, Hennequin L F, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyro-sine kinase inhibitor for the treatment of cancer. Cancer Res. 2005. 65(10):4389-400.
14. Tao LY, Liang YJ, Wang F, et al. Cediranib (recentin, AZD2171) reverses ABCB1-and ABCC1-mediated multidrug resistance by inhibition of their transport function. Cancer Chemother Pharmacol 2009;64:961-969.
15. Adjei AA, Mandrekar SJ, Dy GK, et al. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol 2010;28:614-619.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
17. Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol 2010;28:1835-1842.
18. Available at: http://www.bloomberg.com/apps/news?pid=newsarchive&s id=aUYBejA4gl3M&refer=japan. Accessed May 19, 2012.
19. Scagliotti G, Vynnychenko I, Ichinose Y, et al. An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motes nib plus carbolated/palliate(C/P) in patients with advanced nonsquamous non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29:18s(abstrLBA7512).
20. Goss GD, Arnold A, Shepherd FA, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010;28:49-55.
21. Laurie SA, Solomon BJ, Seymour L, et al. A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR.29. J Clin Oncol 2012; 30S:abstr 7511.
22. Mccarthy SA, Bicknell R. Inhibition of vascular endothelial cell growth by activin-A. J Biol Chem 1993;268:23066-23071.
23. Krneta J, Kroll J, Alvex F, et al. Dissociation of angiogenesis and tumor genesis in follistatin-and activin-expressing tumors. Cancer Res 2006;66:5686-5695.
24. Ogino H, Yano S, Kakiuchi S, et al. Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice. Clin Cancer Res 2008;14:660-667.
25. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008;14:6735-6741.
26. Huang D, Ding Y, Zhou M, et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res 2010;70:1063-1071.
27. Kopetz S, Hoff PM, Morris JS, et al. Phase II trial of infusional fuoroura-cil, irinotecan, and bevacizumab for metastatic colorectal cancer: effcacy and circulating angiogenic biomarkers associated with therapeutic resistance. J Clin Oncol 2010;28:453-459.
28. Bellmunt J, González-Larriba JL, Prior C, et al. Phase II study of suni-tinib as frst-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol 2011;22:2646-2653.
29. Orditura M, De Vita F, Catalano G, et al. Elevated serum levels of inter-leukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res 2002;22:1129-1135.
30. Westermark B, Heldin CH. Platelet-derived growth factor. Structure, function and implications in normal and malignant cell growth. Acta Oncol 1993;32:101-105.
31. Lindahl P, Johansson BR, Levéen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-defcient mice. Science 1997;277:242-245.
32. Nissen LJ, Cao R, Hedlund EM, et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J Clin Invest 2007;117:2766-2777.
33. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8:299-309.
34. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231.
35. Deprimo SE, Bello CL, Smeraglia J, et al. Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. J Transl Med 2007;5:32.
36. Rini BI, Michaelson MD, Rosenberg JE, et al. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 2008;26:3743-3748.
37. Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: fnal effcacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009;27:3312-3318.
38. Peña C, Lathia C, Shan M, Escudier B, Bukowski RM. Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial. Clin Cancer Res 2010;16:4853-4863.
39. Jayson GC, de Haas S, Delmar P, et al. Evaluation of plasma VEGFA as a potential predictive pan-tumour biomarker for bevacizumab. Abstract 804. 2011 European Multidisciplinary Cancer Congress, September 23-27, 2011.
40. Zweifel M, Jayson GC, Reed NS, et al. Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol 2011;22:2036-2041.
41. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fbroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008;14:1407-1412.
42. Mok T, Gorbunova V, Juhasz E, et al. Biomarker analysis in BO21015, a phase II randomized study of frst-line bevacizumab combined with car-boplatin-gemcitabine or carboplatin-paclitaxel in paitents with advanced or recurrent non-squamous non-small cell lung cancer. 2011 European Multidisciplinary Cancer Congress. Abstract 9003. 2011 European Multidisciplinary Cancer Congress, September 23-27, 2011.
43. Kim DH, Xu W, Kamel-Reid S, et al. Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy. Ann Oncol 2010;21:1179-1188.
44. Heist RS, Zhai R, Liu G, et al. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol 2008;26:856-862.
45. Schneider B P, Wang M, Radovich M, et al.; ECOG 2100. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-4678.
46. Sohn J W, Lee SY, Lee SJ, et al. MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 2006;36:137-141.
47. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530-2535.
48. Chen S, Huo X, Lin Y, et al. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients. Int J Hyg Environ Health 2010;213:140-145.
49. Goeke F, Franzen A, Menon R, et al. Rationale for treatment of metastatic squamous cell carcinoma of the lung using FGFR Inhibitors. Chest 2012;.
50. Dutt A, Ramos AH, Hammerman PS, et al. Inhibitor-sensitive FGFR1 ampli-fcation in human non-small cell lung cancer. PLoS ONE 2011;6:e20351.
51. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplifcation associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2:62ra93.